The association between acute gastrointestinal injury and mortality in elderly patients with gram-positive bacterial bloodstream infection in the intensive care unit: a retrospective 7-year study from a research hospital in China.
Yuanqi Liang, Chulong Ma, Tingting Ma, Fan Lin, Tailin Guo
{"title":"The association between acute gastrointestinal injury and mortality in elderly patients with gram-positive bacterial bloodstream infection in the intensive care unit: a retrospective 7-year study from a research hospital in China.","authors":"Yuanqi Liang, Chulong Ma, Tingting Ma, Fan Lin, Tailin Guo","doi":"10.3389/fmed.2025.1634980","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Gram-positive bacterial bloodstream infections (GPB-BSI) are associated with high mortality in elderly ICU patients, yet prognostic factors remain understudied. Acute gastrointestinal injury (AGI), a common complication in critical illness, may exacerbate outcomes through gut-organ crosstalk. This study investigates the prognostic impact of AGI severity on 30-day mortality in elderly ICU patients with GPB-BSI.</p><p><strong>Methods: </strong>A single-center retrospective cohort study analyzed 117 ICU patients aged ≥60 years with culture-confirmed GPB-BSI (2018-2024). Data on demographics, microbiology, comorbidities, organ dysfunction, and antimicrobial therapy were collected. Multivariable Cox regression and ROC analyses assessed associations between AGI, clinical variables, and mortality.</p><p><strong>Results: </strong>The 30-day mortality rate was 50.4% (59/117). AGI severity independently predicted mortality: Grades I-II (aHR = 2.80, 95% CI = 1.05 ~ 7.46) and Grades III-IV (aHR = 6.89, 95%CI = 2.34 ~ 20.29). A combined SOFA-AGI score improved prognostic accuracy compared to SOFA score(AUC = 0.749 vs 0.729). Coagulase-negative staphylococci (60.3%) dominated isolates, predominantly hospital-acquired (79.4%) and catheter-related (47.0%). High resistance to penicillins (92.1%), fluoroquinolones (79.4%), and macrolides (77.0%) contrasted with retained susceptibility to linezolid (96.8%), tigecycline (92.9%), and vancomycin (94.4%).</p><p><strong>Conclusion: </strong>AGI severity is an independent predictor of mortality in elderly GPB-BSI patients. The diagnostic accuracy for mortality improves when gastrointestinal dysfunction assessment is incorporated into the SOFA score. These findings underscore the critical need for enhanced clinical attention to gastrointestinal function protection in geriatric critical ill patients.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1634980"},"PeriodicalIF":3.1000,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12500591/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2025.1634980","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Gram-positive bacterial bloodstream infections (GPB-BSI) are associated with high mortality in elderly ICU patients, yet prognostic factors remain understudied. Acute gastrointestinal injury (AGI), a common complication in critical illness, may exacerbate outcomes through gut-organ crosstalk. This study investigates the prognostic impact of AGI severity on 30-day mortality in elderly ICU patients with GPB-BSI.
Methods: A single-center retrospective cohort study analyzed 117 ICU patients aged ≥60 years with culture-confirmed GPB-BSI (2018-2024). Data on demographics, microbiology, comorbidities, organ dysfunction, and antimicrobial therapy were collected. Multivariable Cox regression and ROC analyses assessed associations between AGI, clinical variables, and mortality.
Results: The 30-day mortality rate was 50.4% (59/117). AGI severity independently predicted mortality: Grades I-II (aHR = 2.80, 95% CI = 1.05 ~ 7.46) and Grades III-IV (aHR = 6.89, 95%CI = 2.34 ~ 20.29). A combined SOFA-AGI score improved prognostic accuracy compared to SOFA score(AUC = 0.749 vs 0.729). Coagulase-negative staphylococci (60.3%) dominated isolates, predominantly hospital-acquired (79.4%) and catheter-related (47.0%). High resistance to penicillins (92.1%), fluoroquinolones (79.4%), and macrolides (77.0%) contrasted with retained susceptibility to linezolid (96.8%), tigecycline (92.9%), and vancomycin (94.4%).
Conclusion: AGI severity is an independent predictor of mortality in elderly GPB-BSI patients. The diagnostic accuracy for mortality improves when gastrointestinal dysfunction assessment is incorporated into the SOFA score. These findings underscore the critical need for enhanced clinical attention to gastrointestinal function protection in geriatric critical ill patients.
期刊介绍:
Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate
- the use of patient-reported outcomes under real world conditions
- the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines
- the scientific bases for guidelines and decisions from regulatory authorities
- access to medicinal products and medical devices worldwide
- addressing the grand health challenges around the world